Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2016
Pharma News, 2016
Britain first country to approve 'three-parent' babies
Britain is set to become the first country in the world to legally offer "three-parent baby" fertility treatments after regulators gave the green light.
FDA approves Eucrisa for eczema
The U.
Gilead and Express Scripts make peace in hep C with 2017 formulary deal
It’s official.
NANOBIOTIX reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers trial
PARIS, France and CAMBRIDGE, MA, USA I December 14, 2016 I NANOBIOTIX (Euronext.
Intercept Pharma's liver drug wins conditional EU approval
Intercept Pharmaceuticals Inc said its liver drug received conditional approval from the European Commission to treat patients with primary biliary cholangitis (PBC), a rare liver condition.
Sanofi in talks with Actelion, sources say
French pharmaceutical company Sanofi is in talks with Swiss drugmaker Actelion, but a deal is not imminent, sources confirmed to CNBC on Wednesday.
Cognition Therapeutics initiates US clinical testing of CT1812, a novel small molecule for the potential treatment of Alzheimer's disease
PITTSBURGH, PA, USA I December 13, 2016 I Cognition Therapeutics, Inc.
Switzerland’s Lonza would pay over $5 billion for drug-capsule maker
Private-equity firm KKR & Co.
Bayer, Versant invest $225 million in biotech venture
German healthcare group Bayer said on Monday it has set up a joint venture with U.
Achaogen's lead antibiotic succeeds two key studies; shares soar
Achaogen Inc's lead antibiotic was successful in two key studies, spurring the company to proceed with regulatory submissions in the United States and Europe, and shares soared 76 percent to their...
EIP Pharma announces positive results with neflamapimod (VX-745) in two Phase 2a clinical trials in patients with Early Alzheimer's Disease
CAMBRIDGE, MA, USAI December 8, 2016 I EIP Pharma, LLC (www.
Pharma’s bad jobs week gets worse: AstraZeneca to cut 700 U.S. positions
AstraZeneca’s $1.
1
2
3
4
5
6
7
